Here we investigate the recently described ALK inhibitor PF-06463922 (lorlatinib) in neuroblastoma driven by expression of wild-type or mutant ALK, with a focus on whether PF-06463922 is more effective than crizotinib against those mutants known to confer crizotinib resistance. The gene discussed is ALK; the disease is neuroblastoma.